# Diabetes Research Hub — Daily Monitor Report
**Date:** 2026-03-16
**Previous report:** 2026-03-15
**Data sources:** Hub file system, ClinicalTrials.gov snapshots, PubMed snapshots, web search

---

## File System Status

| File | Last Modified | Status |
|------|--------------|--------|
| hub_monitor_report.md | 2026-03-16 09:04 | Fresh (updated today) |
| clinical_trials_latest.json | 2026-03-15 00:45 | Current |
| clinical_trials_snapshot_2026-03-16.json | 2026-03-16 09:03 | Fresh (new today) |
| pubmed_recent_latest.json | 2026-03-15 00:46 | Current |
| pubmed_recent_snapshot_2026-03-16.json | 2026-03-16 09:03 | Fresh (new today) |
| literature_gap_data.json | 2026-03-15 00:45 | Current (1 day old) |
| literature_gap_report.md | 2026-03-15 23:50 | Current |
| Diabetes_Research_Tracker.xlsx | 2026-03-15 22:46 | Current |
| Research_Findings_Summary.md | 2026-03-15 23:50 | Current |

**Hub growth since last scan:** 43 new files detected. Total tracked files: 47. The hub now includes 16 Python scripts, 7 HTML dashboards (including Clinical Trial Dashboard, Equity Map, Gap Deep Dives, Gap Synthesis, Acronym Database, Medical Data Dictionary, and Research Dashboard), and comprehensive analysis outputs.

**No missing or stale files.** All script outputs are within 2 days.

---

## Clinical Trial Changes (Mar 15 → Mar 16)

**Total tracked trials:** 746 (unchanged from yesterday)

**No new trials, no removed trials, no status changes, and no new results posted** since the March 15 snapshot. The trial landscape is stable day-over-day.

### Key Phase 3 Recruiting Trials (42 total)

Priority trials from key organizations currently recruiting:

| NCT ID | Title | Sponsor | Notes |
|--------|-------|---------|-------|
| NCT06832410 | Efficacy, Safety, Tolerability of VX-880 | Vertex Pharmaceuticals | Zimislecel Phase 3 — highest priority T1D cure trial |
| NCT04786262 | Safety, Tolerability, Efficacy of VX-880 | Vertex Pharmaceuticals | Original VX-880 Phase 1/2/3 trial |
| NCT07222137 | Baricitinib for Delay of Stage 3 T1D | Eli Lilly | JAK inhibitor for T1D prevention |
| NCT05819138 | T1D Impacts of Semaglutide on CV Outcomes | Univ. of Colorado | GLP-1 in T1D — CV outcomes focus |
| NCT06951074 | Insulin Producing Stem Cell Transplant in T1D | Ain Shams University | Phase 3 stem cell trial |
| NCT07258394 | Dimethyl Fumarate Preserving β-Cell Function | Nanjing Medical Univ. | Drug repurposing — relevant to Tier 1 area |
| NCT06630585 | GIP/GLP-1RA Adjunctive to AID in T1D | University of Bern | Multi-agonist + automated delivery |
| NCT06217302 | Sotagliflozin to Slow Kidney Decline in T1D | Alessandro Doria | SGLT2 inhibitor for T1D kidney protection |

### Category Breakdown (unchanged)

| Category | Count |
|----------|-------|
| Diabetes Technology (Devices) | 217 |
| Diabetes Recently Completed with Results | 244 |
| T1D Cure & Cell Therapy | 154 |
| T2D Novel Therapies (Phase 2-3) | 133 |
| T1D Immunotherapy & Prevention | 71 |

---

## PubMed Highlights (Mar 15 → Mar 16)

**Total unique papers:** 124 (+2 from yesterday's 122)
**26 new papers entered** the rolling 30-day window; 24 dropped out.

### Domain Volume Changes

| Domain | Count | Change | Signal |
|--------|-------|--------|--------|
| Diabetes AI/ML | 180 | +6 | HIGH — surging |
| Diabetes Microbiome | 140 | +3 | HIGH |
| Diabetes Biomarker | 128 | +3 | HIGH |
| Diabetes Epigenetics | 5 | +3 | Notable uptick (from 2) |
| T2D GLP-1 New | 146 | -3 | Still high |
| T2D Remission | 51 | -1 | Active |
| Diabetes Drug Repurpose | 2 | -1 | LOW — remains underserved |
| LADA New Research | 8 | 0 | LOW — consistent with gap analysis |

### Cross-Domain Papers (Highest Priority)

These papers span multiple research domains — highest value for synthesis:

1. **"Multi-omics analysis of dynamic profiles in response to various nutrient loads provides novel insights into obesity."** — Spans Diabetes Biomarker, Diabetes Microbiome, Diabetes Multi-Omics. Directly relevant to Tier 1 area (Multi-Omics Biomarker Integration). [PubMed 41825203](https://pubmed.ncbi.nlm.nih.gov/41825203/)

2. **"Modulating immune response for the prevention and treatment of type 1 diabetes."** — Spans T1D Stem Cell Cure, T1D Immunotherapy. Review bridging two T1D treatment modalities. [PubMed 41777899](https://pubmed.ncbi.nlm.nih.gov/41777899/)

3. **"The New Wave of Gene and Cell Therapies Across Diseases."** — Spans T1D Immunotherapy, Diabetes Gene Therapy. [PubMed 41827217](https://pubmed.ncbi.nlm.nih.gov/41827217/)

4. **"Polysaccharide from [plant source]"** — NEW today. Spans Diabetes Biomarker, Diabetes Microbiome, Diabetes Complications New. Triple-domain paper. [PubMed 41834408](https://pubmed.ncbi.nlm.nih.gov/41834408/)

5. **"Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance..."** — Spans T2D GLP-1 New, T2D Remission. [PubMed 41828377](https://pubmed.ncbi.nlm.nih.gov/41828377/)

### Key Therapy Mentions

| Therapy | Papers Found | Notes |
|---------|-------------|-------|
| **Teplizumab (Tzield)** | 1 | Clinical practice experience in Stage 2 T1D (3 adults) — PMID 41796109 |
| **Semaglutide** | 1 (LADA) | Use as add-on therapy in LADA patients — PMID 41729594 |
| **Canagliflozin (SGLT2i)** | 1 | Promotes β-cell regeneration in polygenic T2D model — PMID 41814144 |
| Zimislecel | 0 | No new publications (trial ongoing) |
| Orforglipron | 0 | No new publications (Phase 3 in progress) |
| Retatrutide | 0 | No new publications |
| CagriSema | 0 | No new publications |
| Baricitinib | 0 | No new publications (Phase 3 recruiting per NCT07222137) |

### Notable New Papers Today (Mar 16)

- **"Use of continuous glucose monitoring to stratify individuals without diabetes."** (Communications Medicine) — AI/ML + CGM for pre-diabetes stratification. Directly relevant to Tier 1 AI/ML Prediction Model Development.
- **"High-Fidelity Synthetic Data Replicates Clinical Prediction Performance in a Military Population."** (Advanced Science) — AI/ML methodology for clinical prediction using synthetic data.
- **"Fructose-induced prediabetes causes persistent DNA methylation changes in white [tissue]."** (Molecular and Cellular Endocrinology) — Epigenetics of prediabetes, relevant to Tier 2 Epigenetic Data Mining.
- **"T2DM-Induced Gut Dysbiosis Exacerbates Periodontitis Through Intestinal Barrier [damage]."** (J Clinical Periodontology) — Microbiome-complications link.
- **"Cross-Trait Genome-Wide Association Studies Identify Shared Genetic Risk Loci..."** (Metabolic Syndrome and Related Disorders) — GWAS cross-trait work, relevant to polygenic risk.

---

## Gap Analysis Summary

**Analysis date:** 2026-03-15 (1 day old — current)
**Domains analyzed:** 30 | **Pairs analyzed:** 435

### Top 5 Under-Researched Intersections

| Rank | Domain 1 | Domain 2 | Gap Score | Joint Pubs | Tier 1 Alignment |
|------|----------|----------|-----------|------------|-------------------|
| 1 | Beta Cell Regen | Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 2 | Insulin Resistance | Islet Transplant | 100.0 | 1 | Partial — Clinical Trial Intelligence |
| 3 | Islet Transplant | Drug Repurposing | 100.0 | 0 | **Yes — Drug Repurposing Screen (Tier 1 #4)** |
| 4 | Islet Transplant | Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 5 | Gene Therapy | LADA | 100.0 | 0 | Partial — Literature Synthesis |

**Key alignment with Tier 1 contribution areas:**

- **Gap #3 (Islet Transplant × Drug Repurposing)** directly aligns with Project 4 (Drug Repurposing Screen). Computational screening of existing immunosuppressants for islet-protective properties is actionable now.
- **Gaps #1, #4 (Health Equity intersections)** align with Tier 1 #6 (Epidemiological Data Analysis). These are systematically absent and represent strong Contribution Strategy targets.
- **LADA gaps (#5 and others)** are consistent with PubMed data showing only 8 LADA publications in the last 30 days and 535 total since 2020. LADA remains the most neglected diabetes subtype.
- **Drug Repurposing domain** shows only 2-3 papers per month — confirming it as a high-gap, high-opportunity area.

---

## Breaking News (Last 7 Days)

### Significant Developments

1. **MUSC Receives $1M from Breakthrough T1D for Two-Part T1D Cure Approach** (March 2026)
   Researchers at the Medical University of South Carolina are developing lab-made insulin-producing cells paired with custom-engineered immune "bodyguard" cells — aiming for transplant without immunosuppression. This aligns with our tracked Vertex/Sana approaches. *Validation level: BRONZE (single news source; awaiting peer-reviewed publication).*

2. **Ozempic Tablets (Oral Semaglutide) FDA Approved** (February 2026)
   Novo Nordisk's oral semaglutide approved for T2D, with US availability expected Q2 2026. A supplemental 25 mg tablet application is under FDA review. *Validation level: SILVER (FDA action confirmed by multiple sources).*

3. **Medtronic MiniMed 780G Expanded Clearances** (February 2026)
   Three milestones: Medicare access, FDA clearance for ultra-rapid insulin use, and clearance for insulin-requiring T2D. Expands the closed-loop ecosystem significantly. *Validation level: SILVER (FDA clearance confirmed).*

4. **Orforglipron, CagriSema, and Retatrutide Approaching FDA Decisions** (2026)
   All three key therapies tracked in our pipeline are advancing toward expected FDA action in 2026. No specific approval dates announced yet. *Validation level: BRONZE (industry forward-looking statements).*

5. **ATTD 2026 Conference (Barcelona)** — Dexcom G7 registry data shows long-term CGM use supports weight management and lowers A1C in non-insulin T2D. Dexcom Smart Basal feasibility study positive.

6. **ADA Standards of Care 2026 Released** — Key updates include CGM recommended at diabetes onset, removal of prerequisites for insulin pump initiation, and new guidance for glucose-lowering in CKD. *Action: Verify hub findings against updated 2026 Standards.*

7. **ASC30 (Ascletis Pharma) — FDA IND Clearance** for Phase II oral small molecule GLP-1 trial. Enrollment expected Q1 2026. A new entrant in the competitive oral GLP-1 space.

---

## Recommended Actions

### High Priority

1. **Verify hub against ADA Standards of Care 2026.** The updated standards include significant changes (CGM at onset, pump access expansion, CKD guidance). Per Research Doctrine Section F, all findings should be reviewed for consistency with current guidelines.
   → Action: Review Research_Findings_Summary.md against 2026 Standards

2. **Add MUSC Breakthrough T1D-funded cure project to tracker.** The two-part approach (stem cell β-cells + engineered immune cells) is a new entrant worth tracking alongside Vertex and Sana.
   → Action: Update Diabetes_Research_Tracker.xlsx with new pipeline entry

3. **Review cross-domain paper PMID 41834408** — today's new triple-domain paper (Biomarker × Microbiome × Complications). High synthesis value.
   → Action: Ingest per Research Doctrine Section A

### Medium Priority

4. **Update tracker with oral semaglutide FDA approval.** This is a confirmed regulatory action that should be logged.
   → Action: Update Pipeline sheet in tracker

5. **Review teplizumab clinical practice paper (PMID 41796109).** Real-world experience data for Tzield in Stage 2 T1D (3 adults). Small N but clinically relevant.
   → Action: Ingest and assess evidence level (likely Level 3 — case series)

6. **Review CGM stratification paper (PMID 41832215).** "Use of continuous glucose monitoring to stratify individuals without diabetes" — directly relevant to Tier 1 AI/ML work.
   → Action: Ingest and evaluate for Project 5 relevance

7. **Consider re-running PubMed alerts.** The pubmed_recent_latest.json is from Mar 15 while the snapshot is from Mar 16, indicating the scripts ran today. Both are current. No action needed unless data staleness exceeds 3 days.

### Low Priority / Monitoring

8. **Clinical trials are stable.** No changes in the 746-trial dataset over 24 hours. This is expected behavior for a daily scan. Continue monitoring.

9. **Drug Repurposing domain remains at very low activity** (2-3 papers/month). This confirms the gap analysis finding and supports prioritizing Project 4 (Drug Repurposing Screen).

10. **LADA continues to be neglected** in the literature (8 papers/30 days; 535 total since 2020). The semaglutide-as-add-on paper (PMID 41729594) is noteworthy and should be ingested.

---

## Scripts Status

All scripts are present and accounted for. No scripts need to be run — the latest data was refreshed today (Mar 16).

| Script | Last Output | Status |
|--------|------------|--------|
| hub_monitor.py | 2026-03-16 09:04 | ✓ Current |
| baseline_clinical_trials.py | 2026-03-16 09:03 | ✓ Current |
| baseline_pubmed_alerts.py | 2026-03-16 09:03 | ✓ Current |
| project1_literature_gap_analysis.py | 2026-03-15 00:45 | ✓ Current (1 day) |

---

*Generated by Diabetes Research Hub daily monitor — 2026-03-16*
*Methodology: Research Doctrine v1.0 — Evidence levels noted per CEBM hierarchy*
